Cancer Immunotherapy: Technologies and Global Markets
商品番号 : SMB-76773
| 出版社 | BCC Research |
| 出版年月 | 2025年4月 |
| ページ数 | 203 |
| 図表数 | 227 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,650 |
| 種別 | 英文調査報告書 |
本レポートは、がん免疫療法市場の詳細な分析を提供します。がん免疫療法の現在および将来の市場ポテンシャルを明らかにし、規制状況、推進要因、制約要因、そして機会を網羅した競争環境を分析します。2023年のデータと2024年の予測に基づき、2024～2029年の予測期間におけるがん免疫療法の市場動向を示します。さらに2029年までの年平均成長率（CAGR）予測に加え、主要企業の市場シェアも示しています。
世界のがん免疫療法市場は2024年から2029年の予測期間中に11.4%の年平均成長率（CAGR）で成長し、2024年の1,442億ドルから2029年末までに2,472億ドルに達するとBCC Researchでは予測しています。
「がん免疫療法の技術と世界市場 – Cancer Immunotherapy: Technologies and Global Markets」は世界のがん免疫療法市場を調査し、主要セグメント別に分析・予測を行ったBCC Research（BCCリサーチ）の市場調査レポートです。
調査対象セグメント
- 治療法
- モノクローナル抗体
- 養子免疫細胞療法
- サイトカイン治療
- がんワクチン
- 腫瘍溶解性ウイルス療法
- その他の免疫療法
- がんの種類
- メラノーマ
- 白血病
- リンパ腫
- 骨髄腫（ミエローマ）
- 肺がん
- 乳がん
- 大腸がん
- その他のがん
- 地域
- 北米
- 米国
- カナダ
- メキシコ
- アジア太平洋地域
- 日本
- インド
- 中国
- 韓国
- オーストラリア
- 欧州
- フランス
- ドイツ
- 英国
- イタリア
- スペイン
- その他の地域（RoW）
- 南米
- 中東＆アフリカ
- 北米
調査対象企業
- ABBVIE INC.
- AMGEN INC.
- ASTRAZENECA
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- JOHNSON & JOHNSON SERVICES INC.
- LILLY MERCK & CO. INC.
- NOVARTIS AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
- SANOFI
- 武田薬品工業株式会社
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
Report Highlights
The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.
Report Scope
This report provides a detailed analysis of the cancer immunotherapy market. It highlights cancer immunotherapy’s current and future market potential and analyzes the competitive environment, covering regulatory scenarios, drivers, restraints and opportunities. The report provides market trends in cancer immunotherapy for the forecast period 2024–2029 using data from 2023 and estimates from 2024. It includes projections of compound annual growth rates (CAGRs) through 2029 and provides the market shares of key players in this market.
In this analysis, the cancer immunotherapy market is segmented by therapy types, cancer types and geographic regions. By therapy type, the market is segmented into the following: checkpoint inhibitors, monoclonal antibodies, adoptive cell therapies, cytokine therapy, cancer vaccines, oncolytic virus therapy and other immunotherapies. It is segmented by cancer type into melanoma, leukemia, lymphoma, myeloma, lung cancer, breast cancer, colorectal cancer and other cancers.
The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The regional analysis includes details about major countries such as the U.S., Canada, Germany, the U.K., Italy, Spain, France, Japan, China, South Korea, Australia and India.
The report aims to:
– Analyze therapies and types of cancer.
– Analyze global market size and segmentation.
– Understand market constraints and drivers.
– Provide detailed market forecasts for 2029.
– Assess market shares, competitiveness and industry structure.
– Identify potential long-term impacts on the cancer immunotherapy market.
Report Includes
– 75 data tables and 54 additional tables
– An analysis of the global cancer immunotherapy market
– Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
– Estimates of the market size and revenue prospects for the global market, along with a market share analysis by therapy type, cancer type, and region
– Coverage of treatments that are in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends
– Evaluation of recent patent activity and key granted and published patents in the industry
– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
– Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
– Profiles of leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., and AstraZeneca
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Porter’s Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry
Key Concepts of Immunotherapy
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Cancer Cases Globally
Robust Approval of Immunotherapy Drugs
Rise in Government Funding and Pharmaceutical R&D Spending
Market Restraints
High Cost of Immunotherapy
Loss of Exclusivity and Genericization
Shortage of Oncology Professionals
Market Opportunities
Technological Advances in Immunotherapy
Potential in Cancer Immunotherapy
Chapter 4 Regulatory Landscape
Overview
U.S.
Europe
Japan
Chapter 5 Emerging Technologies
Overview
Artificial Intelligence (AI)
Emergent Biomarkers
Immunotherapy Pipeline
Patent Analysis
Future Prospects
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Market for Cancer Immunotherapy, by Therapy Type
Global Market Size and Forecast
Checkpoint Inhibitors
Monoclonal Antibodies
Adoptive Cell Therapies
Cytokine Therapy
Cancer Vaccines
Oncolytic Virus Therapy
Other Immunotherapies
Global Market for Cancer Immunology, by Cancer Type
Global Market Size and Forecast
Melanoma
Leukemia
Lymphoma
Myeloma
Lung Cancer
Breast Cancer
Colorectal Cancer
Other Cancers
Geographic Breakdown
Global Market for Cancer Immunotherapy, by Region
Global Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Overview
Competitive Landscape
Company Share Analysis
Chapter 8 Sustainability in Cancer Immunotherapy Market: An ESG Perspective
Introduction to ESG
Role of ESG in the Pharma Industry
Sustainability in the Cancer Immunotherapy Market
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
- HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
List of Tables
Summary Table : Global Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 1 : Porter’s Five Forces Analysis: Cancer Immunotherapy Market
Table 2 : Average Price of Immunotherapy
Table 3 : List of Selected Clinical Trial Studies on Immunotherapy, 2025
Table 4 : List of Selected Recent Patents Related to Immunotherapy 2024-2025
Table 5 : Global Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 6 : FDA-Approved Immune Checkpoint Inhibitors 2015–2018
Table 7 : Global Market for Checkpoint Inhibitors in Cancer Immunotherapy, by Region, Through 2029
Table 8 : Global Market for Checkpoint Inhibitors in Cancer Immunotherapy, by Type, Through 2029
Table 9 : Global Market for Monoclonal Antibodies in Cancer Immunotherapy, by Region, Through 2029
Table 10 : Global Market for Adoptive Cell Therapies in Cancer Immunotherapy, by Region, Through 2029
Table 11 : Global Market for Cytokine Therapy in Cancer Immunotherapy, by Region, Through 2029
Table 12 : Global Market for Cancer Vaccines in Cancer Immunotherapy, by Region, Through 2029
Table 13 : Players Investing in Oncolytic Virology, 2024
Table 14 : Global Market for Oncolytic Virus Therapy in Cancer Immunotherapy, by Region, Through 2029
Table 15 : Global Market for Other Immunotherapies in Cancer Immunotherapy, by Region, Through 2029
Table 16 : Global Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 17 : Global Market for Cancer Immunotherapy in Melanoma, by Region, Through 2029
Table 18 : Global Market for Cancer Immunotherapy in Leukemia, by Region, Through 2029
Table 19 : Global Market for Cancer Immunotherapy in Lymphoma, by Region, Through 2029
Table 20 : Global Market for Cancer Immunotherapy in Myeloma, by Region, Through 2029
Table 21 : Global Market for Cancer Immunotherapy in Lung Cancer, by Region, Through 2029
Table 22 : Global Market for Cancer Immunotherapy in Breast Cancer, by Region, Through 2029
Table 23 : Global Market for Cancer Immunotherapy in Colorectal Cancer, by Region, Through 2029
Table 24 : Global Market for Cancer Immunotherapy in Other Cancers, by Region, Through 2029
Table 25 : Global Market for Cancer Immunotherapy, by Region, Through 2029
Table 26 : North American Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 27 : North American Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 28 : North American Market for Cancer Immunotherapy, by Country, Through 2029
Table 29 : U.S. Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 30 : U.S. Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 31 : Canadian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 32 : Canadian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 33 : Mexican Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 34 : Mexican Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 35 : European Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 36 : European Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 37 : European Market for Cancer Immunotherapy, by Country, Through 2029
Table 38 : German Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 39 : German Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 40 : U.K. Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 41 : U.K. Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 42 : French Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 43 : French Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 44 : Italian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 45 : Italian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 46 : Spanish Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 47 : Spanish Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 48 : Rest of European Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 49 : Rest of European Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 50 : Asia-Pacific Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 51 : Asia-Pacific Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 52 : Asia-Pacific Market for Cancer Immunotherapy, by Country, Through 2029
Table 53 : Chinese Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 54 : Chinese Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 55 : Japanese Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 56 : Japanese Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 57 : Indian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 58 : Indian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 59 : Australian Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 60 : Australian Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 61 : Rest of Asia-Pacific Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 62 : Rest of Asia-Pacific Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 63 : Rest of the World Market for Cancer Immunotherapy, by Therapy Type, Through 2029
Table 64 : Rest of the World Market for Cancer Immunotherapy, by Cancer Type, Through 2029
Table 65 : Key Focus Areas in ESG Metrics
Table 66 : ESG Rankings for Leading Companies in Cancer Immunotherapy Market, 2024*
Table 67 : Abbreviations Used in this Report.
Table 68 : Report Sources
Table 69 : AbbVie Inc.: Company Snapshot
Table 70 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 71 : AbbVie Inc.: Product Portfolio
Table 72 : AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 73 : Amgen Inc.: Company Snapshot
Table 74 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 75 : Amgen Inc.: Product Portfolio
Table 76 : Amgen Inc.: News/Key Developments, 2022-2024
Table 77 : AstraZeneca: Company Snapshot
Table 78 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 79 : AstraZeneca: Product Portfolio
Table 80 : AstraZeneca: News/Recent Developments, 2023 and 2024
Table 81 : Bristol-Myers Squibb Co.: Company Snapshot
Table 82 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 83 : Bristol-Myers Squibb Co.: Product Portfolio
Table 84 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 85 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 86 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 87 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 88 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022–2024
Table 89 : Gilead Sciences Inc.: Company Snapshot
Table 90 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 91 : Gilead Sciences Inc.: Product Portfolio
Table 92 : Gilead Sciences Inc.: News/Key Developments, 2023 and 2024
Table 93 : Johnson & Johnson Services Inc.: Company Snapshot
Table 94 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 95 : Johnson & Johnson Services Inc.: Product Portfolio
Table 96 : Johnson & Johnson Services Inc.: News/Key Developments, 2022−2024
Table 97 : Lilly: Company Snapshot
Table 98 : Lilly: Financial Performance, FY 2022 and 2023
Table 99 : Lilly: Product Portfolio
Table 100 : Lilly: News/Key Developments, 2022 and 2023
Table 101 : Merck & Co. Inc.: Company Snapshot
Table 102 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 103 : Merck & Co. Inc.: Product Portfolio
Table 104 : Merck & Co. Inc.: News/Key Developments, 2021–2024
Table 105 : Novartis AG: Company Snapshot
Table 106 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 107 : Novartis AG: Product Portfolio
Table 108 : Novartis AG: News/Key Developments, 2022
Table 109 : Pfizer Inc.: Company Snapshot
Table 110 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 111 : Pfizer Inc.: Product Portfolio
Table 112 : Pfizer Inc.: News/Key Developments, 2023 and 2024
Table 113 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 114 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 115 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 116 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
Table 117 : Sanofi: Company Snapshot
Table 118 : Sanofi: Financial Performance, FY 2022 and 2023
Table 119 : Sanofi: Product Portfolio
Table 120 : Sanofi: News/Key Developments, 2022–2024
Table 121 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 122 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 123 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 124 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023
Table 125 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 126 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 127 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 128 : Few Emerging Players in Cancer Immunotherapy Market
List of Figures
Summary Figure : Global Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 1 : Snapshot of Market Dynamics
Figure 2 : Distribution Share of the Most Frequent Cancer Types in Women*, 2022
Figure 3 : Distribution Share of the Most Frequent Cancer Types in Men*, 2022
Figure 4 : Estimated New Cancer Cases and Deaths in the U.S. in 2024
Figure 5 : National Cancer Institute Research Funding, 2012-2019
Figure 6 : Global Pharmaceutical R&D Spending and Growth, 2020-2026
Figure 7 : Immunotherapy-Related Patents and Publications in the U.S. and China
Figure 8 : Global Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 9 : Global Market Shares of Checkpoint Inhibitors in Cancer Immunotherapy, by Region, 2023
Figure 10 : Global Market Shares of Checkpoint Inhibitors in Cancer Immunotherapy, by Type, 2023
Figure 11 : Global Market Shares of Monoclonal Antibodies in Cancer Immunotherapy, by Region, 2023
Figure 12 : Global Market Shares of Adoptive Cell Therapies in Cancer Immunotherapy, by Region, 2023
Figure 13 : Global Market Shares of Cytokine Therapy in Cancer Immunotherapy, by Region, 2023
Figure 14 : Global Market Shares of Cancer Vaccines in Cancer Immunotherapy, by Region, 2023
Figure 15 : Global Market Shares of Oncolytic Virus Therapy in Cancer Immunotherapy, by Region, 2023
Figure 16 : Global Market Shares of Other Immunotherapies in Cancer Immunotherapy, by Region, 2023
Figure 17 : Global Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 18 : Global Market Shares of Cancer Immunotherapy in Melanoma, by Region, 2023
Figure 19 : Global Market Shares of Cancer Immunotherapy in Leukemia, by Region, 2023
Figure 20 : Global Market Shares of Cancer Immunotherapy in Lymphoma, by Region, 2023
Figure 21 : Global Market Shares of Cancer Immunotherapy in Myeloma, by Region, 2023
Figure 22 : Global Market Shares of Cancer Immunotherapy in Lung Cancer, by Region, 2023
Figure 23 : Global Market Shares of Cancer Immunotherapy in Breast Cancer, by Region, 2023
Figure 24 : Global Market Shares of Cancer Immunotherapy in Colorectal Cancer, by Region, 2023
Figure 25 : Global Market Shares of Cancer Immunotherapy in Other Cancers, by Region, 2023
Figure 26 : Global Market Shares of Cancer Immunotherapy, by Region, 2023
Figure 27 : North American Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 28 : North American Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 29 : North American Market Shares of Cancer Immunotherapy, by Country, 2023
Figure 30 : U.S. Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 31 : U.S. Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 32 : Canadian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 33 : Canadian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 34 : Mexican Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 35 : Mexican Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 36 : European Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 37 : European Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 38 : European Market Shares of Cancer Immunotherapy, by Country, 2023
Figure 39 : German Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 40 : German Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 41 : U.K. Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 42 : U.K. Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 43 : French Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 44 : French Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 45 : Italian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 46 : Italian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 47 : Spanish Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 48 : Spanish Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 49 : Rest of European Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 50 : Rest of European Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 51 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 52 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 53 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Country, 2023
Figure 54 : Chinese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 55 : Chinese Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 56 : Japanese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 57 : Japanese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 58 : Indian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 59 : Indian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 60 : Australian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 61 : Australian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 62 : Rest of Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 63 : Rest of Asia-Pacific Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 64 : Rest of the World Market Shares of Cancer Immunotherapy, by Therapy Type, 2023
Figure 65 : Rest of the World Market Shares of Cancer Immunotherapy, by Cancer Type, 2023
Figure 66 : Top 10 Blockbuster Cancer Immunotherapy Products, by Sales Revenue, 2022-2023
Figure 67 : Global Market Shares of Cancer Immunotherapy, by Company, 2023
Figure 68 : Pillars of ESG
Figure 69 : Advantages of ESG for Companies
Figure 70 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 71 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 72 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
Figure 73 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 74 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
Figure 75 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
Figure 76 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
Figure 77 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 78 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 79 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 80 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 81 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 82 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
Figure 83 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
Figure 84 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 85 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 86 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
Figure 87 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
Figure 88 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 89 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 90 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 91 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 92 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 93 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
Figure 94 : Sanofi: Revenue Share, by Business Unit, FY 2023
Figure 95 : Sanofi: Revenue Share, by Country/Region, FY 2023
Figure 96 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 97 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023
Figure 98 : Teva Pharmaceutical Industries Ltd.: Market Share, by Business Unit, FY 2023
Figure 99 : Teva Pharmaceutical Industries Ltd.: Market Share, by Country/Region, FY 2023
BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。
ライセンス別価格表
2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
新価格表
ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 4,650 | USD 5,580 | USD 6,696 | USD 8,035 |
ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,950 | USD 3,540 | USD 4,248 | USD 5,098 |
ライセンスタイプ3
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,500 | USD 3,000 | USD 3,600 | USD 4,320 |
旧価格表
旧ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 5,500 | USD 6,600 | USD7.920 | USD 9,504 |
旧ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 3,500 | USD 4,200 | USD 5,040 | USD 6,048 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- 2-5ライセンス
- 同一企業内5名までレポートファイルのご利用が可能です。
- サイトライセンス
- 同一企業同住所内でレポートファイルのご利用が可能です。
- エンタープライズライセンス
- 同一企業内人数無制限でレポートファイルのご利用が可能です。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後3営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 持続可能エネルギーの調査レビュー 2024年 2025-04-22
- 世界の燃料電池スタック市場 2025-04-22
- 肝疾患治療の世界市場 2025-04-22
- 細胞と遺伝子の調査レビュー 2024年 2025-04-21
- 美容医療機器：技術と世界市場 2025-04-21